PharmaFrontiers Provides Update, Financial Results
10/19/2005 5:12:42 PM
THE WOODLANDS, Texas--(BUSINESS WIRE)--April 15, 2005--PharmaFrontiers Corp. (OTCBB:PFTR), a company involved in the development and commercialization of cell therapies, today provides an update on its research programs and future plans. In addition, the Company reports financial results for the 12 months ended December 31, 2004.
Research and Development
"We began our journey as a public company during May 2004 with the completion of a reverse merger into a public shell, and strengthened our pipeline of potential therapies for the treatment of several debilitating diseases," said David B. McWilliams, president and chief executive officer of PharmaFrontiers.
In November 2004, the Company acquired Opexa Pharmaceuticals, which held the rights to Tovaxin(TM), a novel autologous therapeutic T cell treatment for multiple sclerosis. Tovaxin(TM) has considerable potential because it attacks the underlying cause of MS rather than just addressing its symptoms. Rights to Tovaxin(TM) originally were obtained under an exclusive, worldwide license from the Baylor College of Medicine in Houston, Texas.